

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 727 486 A2

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:

21.08.1996 Bulletin 1996/34

(21) Application number: 95101980.1

(22) Date of filing: 14.02.1995

(51) Int. Cl.<sup>6</sup>: C12N 15/12, C07K 14/47,  
C12N 5/10, C12P 21/08,  
C12Q 1/68

(84) Designated Contracting States:  
DE FR GB

(71) Applicants:

- CANCER INSTITUTE  
Toshima-ku, Tokyo (JP)
- Eisai Co., Ltd.  
Tokyo 112 (JP)

(72) Inventors:

- Nakamura, Yusuke  
Yokohama-shi, Kanagawa (JP)

- Imai, Takashi  
Narashino-shi, Chiba (JP)

(74) Representative: Hansen, Bernd, Dr. Dipl.-Chem.  
et al  
Hoffmann, Eitle & Partner,  
Patentanwälte,  
Arabellastrasse 4  
81925 München (DE)

Remarks:

The applicant has subsequently filed a sequence  
listing and declared, that it includes no new matter.

(54) Tumour suppressor gene

(57) A detailed genetic map on human chromosome 11 was prepared. Then, a commonly deleted region on the chromosome in the tumor tissues of patients with multiple endocrine neoplasia type 1 was identified. Further, by the linkage analysis on a family line with this disease, a gene causative of this disease was localized. A gene present in the region common to these observations was cloned and the structure of this gene was determined. Because a protein coded by this DNA is homologous with those of transcriptional factors, it is expected that the above-mentioned gene may be a novel tumor suppressor gene. Further, it is also expected that the above-mentioned gene and a protein coded for thereby may be useful in preparations of a remedy for cancer and a diagnostic drug for cancer.

EP 0 727 486 A2

## Description

## Background of the Invention

## 5 Field of the Invention

The present invention relates to a human tumor suppressor gene, a polypeptide coded for thereby and a gene analysis method wherein the above-mentioned gene is used. Thus, they are usable in the field of medicines.

## 10 Description of the Related Art

It has been known for a long time that gene mutation in cells plays an important role in the onset of cancer. Recent advances in genetic engineering have made it possible to amplify specific DNAs and to analyze gene mutation in cancer cells and thus contributed to the remarkable development in the field of studies on cancer.

15 Analysis and identification of oncogenes, which are thought to participate in the cancerization of cells and the abnormal proliferation of cancer cells, are now in progress and the number of the oncogenes thus clarified so far amounts to several tens. On the other hand, tumor suppressor genes having a reverse function have been the focus of intense research interest in these several years. Examples of the tumor suppressor genes which have been found out so far include Rb gene of retinoblastoma [Friend, S.H., et al., Proc. Natl. Acad. Sci. USA, 84, 9095 (1987)], p53 gene [Lane, D.P., et al., Nature, 278, 261 (1979)] and APC gene [Kenneth, W.K., et al., Science, 253, 661 (1991)] of colon cancer and WT1 gene of Wilms' tumor [Call, K.M., et al., Cell, 60, 509 (1990)]. In the case of the p53 gene, it is known that this mutation gene has been handed down over generations as a germ-line in certain family lines ["Li-Fraumeni syndrome"; Makin, D., et al., Science, 250, 1233 (1990); and Srivastava, S., et al., Nature, 348, 747 (1990)]. However, it is considered that there are much more unidentified tumor suppressor genes.

25 Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant hereditary disease characterized by the development of hyperplasia or neoplasm in the endocrine organs such as accessory thyroid, islets of Langerhans in the pancreas and pituitary gland [Brandi, M.L., et al., Endocr. Rev. 8, 391 (1987)]. It is assumed by linkage studies that a genetic defect exists in the long arm of chromosome 11 (11q). Also there is known a region which is deleted with high frequency on chromosome 11q in MEN 1-associated tumors. Based on these facts, it is considered that a tumor suppressor gene exists in this region.

30 Accordingly, it is now the focus of world-wide interest of physicians and researchers to isolate this tumor suppressor gene, to clarify its role in the disease and to clarify its biological function. Thus it has been urgently required to isolate the tumor suppressor gene in this region.

35 It is an object of the present invention to provide a novel tumor suppressor gene, a transformant transformed by a plasmid having, integrated therein, the full structure or part of the tumor suppressor gene, a polypeptide which is coded for by the tumor suppressor gene, an antibody against the polypeptide and methods for studying, examining, diagnosing and medically treating cancer with the use of them.

## 40 Disclosure of the Invention

## Summary of the Invention

45 The present inventors isolated cosmid clones containing a number of RFLP markers on chromosome 11 and prepared a detailed genetic map. By using these newly developed RFLP markers, a region deleted commonly in such tumors was further localized. And, a region where the target tumor suppressor gene existed was restricted to through the linkage analysis. As a result, the region common to these observations was specified as 11q13. From among cosmid clones of this region, those containing exons were selected. By using a fragment thereof as a probe, a cDNA library was screened. Thus a cDNA coding for an amino acid sequence being homologous with transcriptional factors such as human Wilms' tumor suppressor gene (WT1) product and human early growth response protein 2 (EGR2) was isolated.

50 An organism specifically responds to various exogenous and endogenous stimuli by comprehensively utilizing, for example, its nervous, immune, circulatory and endocrine systems. After being input, information is transmitted via the so-called information transmitting system or enters directly into nuclei and thus acts on a gene or a transcriptional factor. As a result, the expression of the gene is modified and thus cells begin to take a turn for the differentiation, proliferation (cancerization) or death. From the very beginning, the process of the ontogeny and morphogenesis of an organism or the sustenance of its life per se is merely the results of the cascade mechanism of gene expression. Thus, it is not too much to say that nothing but "the coordination in gene expression depending mainly on transcription" makes a living organism as it is and cancer breaks out when this coordination falls into disorder.

55 Therefore, we deemed the clone thus isolated as one of tumor suppressor genes, isolated the cDNA thereof in the full length and analyzed the structure thereof. As a result, it has been proved that a protein which is coded for by this

cDNA in the full length is an intranuclear transcriptional regulator having a nuclear localizing signal, a proline-rich domain and a zinc finger motif.

Thus, the present invention relates to:

- 5 (1) a DNA comprising the full structure or a part of the DNA represented by SEQ ID NO:1;
- (2) a polypeptide comprising the full structure or a part of the polypeptide coded for by the DNA represented by SEQ ID NO:1;
- 10 (3) a transformant transformed by a plasmid having, integrated therein, the full structure or a part of the DNA represented by SEQ ID NO:1 which can be expressed therein;
- (4) an antibody against the above-mentioned polypeptide as an antigen; and
- 15 (5) a gene analysis method which comprises using, as a primer, a probe or a marker, a DNA comprising a part of the DNA represented by SEQ ID NO:1 and hybridizing the primer, the probe or the marker with a DNA to be tested.

In other words, the present invention relates to:

- 20 (a) a cDNA which comprises one containing the full or a part of the cDNA of the tumor suppressor gene represented by SEQ ID NO:1;
- (b) a polypeptide which comprises one containing the full or a part of the polypeptide coded for by the cDNA of the tumor suppressor gene represented by SEQ ID NO:1;
- 25 (c) host cells which are obtained by integrating the full or a part of the cDNA described in SEQ ID NO:1 into a plasmid which can express it and transforming thereby;
- (d) an antibody against the polypeptide described in the above item (b) as an antigen; and
- 30 (e) a gene analysis method characterized by using a DNA containing a part of the DNA sequence described in the above item (a) as a primer, a probe or a marker.

With respect to the DNAs and polypeptides, those which are substantially equivalent to the DNAs and polypeptides described above are also included in the scope of the present invention. The expression "DNAs and polypeptides being substantially equivalent" means those which have been modified via, for example, deletion, replacement, addition or insertion of the constituting bases or constituting amino acids and derivatives thereof, which exhibit the same effects as those of the original DNAs or polypeptides. However, the extent of these effects is irrelevant thereto. The term "a part of the DNA" means a fragment composed of at least 10 bases derived from the DNA. In order to employ as a primer, 35 for example, a DNA fragment having a base sequence generally consisting of 10 to 30 bases, preferably 15 to 25 bases, is selected. In order to employ as a probe, a DNA fragment having a base sequence generally consisting of at least 15 bases, preferably at least 20 bases, is selected.

The term "a part of the polypeptide" means a peptide having a sequence composed of at least 6 amino acid residues derived from the polypeptide. When a part of a polypeptide is to be used as an antigen for the preparation of an antibody or as an epitope for the detection of an antibody, it is known that a peptide having a sequence consisting of 6 45 amino acid residues would bind to an antibody [see WO 8403564, published on Sep. 13, 1984 (Assignee: COMMONWEALTH SERUM LABS and GEYSEN, H. M.)]. A peptide having a sequence generally consisting of at least 10 amino acid residues, preferably at least 20 amino acid residues, is employed therefor. Although it may be anticipated that a peptide having a sequence consisting of 6 amino acid residues can achieve only a poor efficiency in the production of an antibody, such a peptide is also usable in the form of a fused peptide. 50

Furthermore, an RNA which comprises one translated from the DNA represented by SEQ ID NO:1 or a part of the same and RNAs which are substantially equivalent thereto are included in the scope of the present invention.

Now the present invention will be described in greater detail.

## Detailed Description of the Invention

## (1) Isolation of cDNA

5 The target cosmid library of the human chromosome 11 can be prepared in, for example, the following manner. From human/mouse hybrid cell line containing a single human chromosome 11 in a mouse genomic background, a chromosomal DNA is extracted. Then DNA fragments of the chromosomal DNA can be integrated into a vector such as pWE15 by a conventional method [Maniatis, T., et al., Molecular Cloning 2nd. ed., Cold Spring Harbor Laboratory Press, N.Y. (1989)]. Clones having an insert originating in the human chromosome can be screened by the colony  
 10 hybridization with the use of a whole human DNA as probe. The thus obtained cosmid clones containing a DNA originating in the human chromosome 11 are then subjected to the fluorescent in-situ hybridization (FISH) method [Takahashi et al., Am. J. Hum. Genet., 86, 14 - 16 (1990)]. Thus, each of the multitude of the cosmid clones can be localized throughout the chromosome and a physical chromosomal map can be prepared. Further, RFLP markers can be isolated on the basis of the fragment length pattern which has been prepared by cleaving human DNA with several restriction  
 15 enzymes [Nakamura et al., Am. J. Hum. Genet., 43, 854 - 859 (1988)]. Among these clones, those located around the region of 11q13 are subjected to the FISH method and the linkage analysis to thereby give a further detailed genetic map. Based on this map, the DNA of a cancer tissue of a patient is examined in the loss of heterozygosity (LOH) by utilizing the RFLP. Thus the region where the target tumor suppressor gene is located can be further restricted to.

From the cosmid clones existing in the region which has been thus restricted to, a DNA fragment being under  
 20 expression can be isolated by the exon trapping method [Buckler, A., et al., Proc. Natl. Acad. Sci. USA, 88, 4005 - 4009 (1991)]. By using the DNA fragment thus obtained as probe, the cDNA of a gene existing in the restricted region near q13 of human chromosome 11 can be cloned.

## (2) Confirmation of the whole structure of the gene

25 The base sequence of the cDNA can be determined by the Maxam-Gilbert method [Maxam, A.M. and Gilbert, W., Proc. Natl. Acad. Sci. USA, 74, 560 (1977)] or the dideoxy technique [Messing, J., Nucleic acid Res., 9, 309 (1981)].

It can be confirmed by, for example, the 5'RACE method, the 3'RACE method or the Northern blotting that the cDNA obtained by the above-mentioned method contains the full length protein translation region.

## (3) Recombinant expression vectors and transformants transformed thereby

30 The tumor suppressor gene cDNA obtained by the above-mentioned method, or a fragment thereof is integrated into an appropriate vector and then this vector is introduced into appropriate host cells to obtain a transformant. By culturing this transformant in a conventional manner, a large amount of the tumor suppressor gene product, or a fragment thereof can be obtained from the culture. More specifically, the cDNA is linked to the downstream side of the promoter of a vector suitable for the expression of the cDNA by a known method with the use of restriction enzymes and DNA ligase. Thus a recombinant expression vector can be constructed. Examples of the vectors usable therefor include plasmids pRB322 and pUC18 originating in *Escherichia coli*, plasmid pUB110 originating in *Bacillus subtilis*, plasmid pRB15  
 40 originating in yeast, phage vectors  $\lambda$ gt10 and  $\lambda$ gt11, and vector SV40 originating in animal virus, though any vector capable of replicating and amplifying in the host cells may be used therefor without restriction. Similarly the promoter and the terminator are not restricted in particular and any suitable combination may be selected therefor depending on the host to be used, so long as they are adapted for the host employed in the expression of a DNA sequence coding for the tumor suppressor gene, or a fragment thereof. Any DNA may be used as the cDNA herein so long as it codes for  
 45 the tumor suppressor gene product, or a fragment thereof. A chemically synthesized one may be used therefor. When the protein to be expressed is one having a physiological activity of suppressing the proliferation of cancer cells, then the sequence of the cDNA is not restricted to the DNA sequence represented by the SEQ ID NO:1 but a DNA having a DNA sequence which has undergone partial substitution, deletion, insertion or a combination thereof may be used therefor as the cDNA.

50 The recombinant expression vector thus obtained is introduced into a host by, for example, the competent cell method [J. Mol. Biol., 53, 154 (1970)], the protoplast method [Proc. Natl. Acad. Sci. USA, 75, 1929 (1978)], the calcium phosphate method [Science, 221, 551 (1983)], the in vitro packaging method [Proc. Natl. Acad. Sci. USA, 72, 581 (1975)] or the virus vector method [Cell, 37, 1053 (1984)] to thereby prepare a transformant. *Escherichia coli*, *Bacillus subtilis*, yeasts and animal cells are usable as the host. The transformant thus obtained is then cultured in an appropriate medium selected depending on the employed host. The culture is usually effected at a temperature of from 20 to 45°C within a pH range of from 5 to 8 and, if necessary, under aeration and/or stirring. The tumor suppressor gene product or a fragment thereof may be separated and purified from the culture by appropriately combining known separation/isolation methods. Examples of these methods include salting out, solvent precipitation, dialysis, gel filtration,  
 55

electrophoresis, ion exchange chromatography, affinity chromatography and reversed phase high performance liquid chromatography.

#### (4) Preparation of antibody

5

By using the tumor suppressor gene product or a fragment thereof as an antigen, an antibody is prepared. A polyclonal antibody is prepared in accordance with a conventional method by, for example, sufficiently immunizing an animal such as mouse, guinea pig and rabbit with the antigen by subcutaneously, intramuscularly, intraperitoneally or intravenously administering it a number of times, sampling the blood from the animal and then separating the serum to obtain the antibody. A commercially available adjuvant is also usable therefor.

10

A monoclonal antibody can be prepared by a known method. For example, spleen cells of a mouse immunized with the antigen described above are fused with commercially available mouse myeloma cells to thereby give hybridomas. Then the target monoclonal antibody can be prepared from the culture supernatant of the hybridoma or the ascites fluid of a mouse inoculated with the hybridoma.

15

It is not necessary that the tumor suppressor gene product to be used as the antigen has the whole amino acid structure but a peptide having a partial structure thereof, a modified peptide, its derivative or a fused peptide formed by fusing this peptide with another peptide are also usable. These substances may be prepared by any of the biological technique and chemical synthesis technique.

20

These antibodies enable the identification and determination of the peptide of the present invention in human biological samples and thus are applicable to, for example, diagnostic drugs for diseases to which the polypeptide is related. The peptide can be immunologically assayed in accordance with any of the known methods including the fluorescent antibody method, the passive agglutination method and the enzyme-labeled antibody technique.

#### (5) Gene analysis of human organic tissues

25

Examples of the biological sample usable in the gene analysis include normal human tissues, various types of human tumor tissues, human blood, human bodily fluids and human secretions. The DNA of the employed tissue may be extracted and prepared by, for example, the method reported by Sato, T., et al. [Cancer Res., 50, 7184 (1990)].

30

From the DNA sequence provided by the present invention, a part DNA sequence at an appropriate position is selected and a synthetic oligonucleotide having this sequence or one complementary thereto is used as a primer, a probe or a marker. Thus the occurrence of a mutation of this gene in man and the morphology of the mutation can be analyzed. Furthermore, alterations (insertion, deletion, etc.) of this gene in a sample can also be detected by these analyses.

35

The part DNA sequence may be selected from any part of the DNA sequence of the above-mentioned gene. It is needless to say that an artificially modified DNA sequence may be used therefor and thus the corresponding gene mutation can be detected.

40

The analysis may be effected by, for example, the following method. Namely, primers of two sequences are selected and the partial sequence between them is amplified by the PCR method. Then the amplified DNA sequence is directly analyzed. Alternatively, this amplification product is integrated into a plasmid in the same manner as that of the above-mentioned case and host cells are transformed thereby. After culturing the transformant thus obtained, the DNA sequence of the clone thus obtained is analyzed. Further, the ligase chain reaction method may be applied to the amplification [Wu et al., Genomics, 4, 560 - 569 (1989)]. Furthermore, a specific mutation in the above-mentioned gene in a sample can be detected by using the allele-specific PCR [Ruano and Kidd, Nucleic Acid Research, 17, 8392 (1989)] or the ARMS method [C.R. Newton et al., Nucleic Acid Research, 17, 2503 - 2517 (1989)].

45

Similarly, a point mutation can be detected by the SSCP method [Orita et al., Proc. Natl. Acad. Sci. USA, 86, 2766 - 2770 (1989); and Genomics, 5, 874 - 879 (1989)] or the RNase-protection method with the use of probes containing the DNA sequence thus selected or an RNA sequence originating therein. By using these probes, a mutation in the above-mentioned gene in a sample can be detected by the Southern hybridization method or an abnormality in the expression level of this gene in a sample can be examined by the Northern hybridization method.

50

*Escherichia coli* DH5 $\alpha$ /pAB1, pFL2 and pCE9 each carrying a plasmid containing the cDNA of this tumor suppressor gene were deposited with National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology, Ministry of International Trade and Industry under accession numbers FERM P-14127, 14128 and 14129, respectively, on February 8, 1994, and they were changed to International deposition under accession numbers FERM BP-4923, 4924 and 4925, respectively, on December 9, 1994.

55

The DNA of the present invention has a structure homologous with those of transcriptional factors, and originates in the most restricted commonly deleted region on chromosome 11 in MEN 1-associated tumors. Therefore, it is expected that the DNA of the present invention may be a novel tumor suppressor gene. The DNA may be used as a tool in a gene therapy. Further, the fragment of the DNA may be used in the gene analysis of the DNA and in the diagnosis of diseases to which the DNA relates.

The polypeptide coded for by the DNA according to the present invention may be used as a reagent for investigations and used for preparing an antibody. The antibody may be used in the qualitative or quantitative analysis of the polypeptide in a biological sample. Thus, it is expected that the antibody may be useful as a novel diagnostic drug.

## 5 Brief Description of the Drawings

Fig. 1 is a diagram showing the restriction of the region in which the MEN1 gene exists by the linkage analysis and the LOH analysis.

Fig. 2 is a diagram showing cDNA clones which overlap one another and the domain structure of ZFM1 cDNA derived therefrom.

Fig. 3 is a diagram showing the homology of the ZFM1 protein with WT1 or EGR2.

Fig. 4 is a diagram showing the constitution of exons of the ZFM1 gene. The exons are represented by 1 to 14. The domains observed in cDNA are represented by A to H.

## 15 Examples

To further illustrate the present invention in greater detail and in particular, the following Examples will be given. However it is to be understood that the present invention is not restricted these Examples only.

### 20 Example 1 Isolation and linkage analysis of cosmid clones specific for chromosome 11

At the early stage of studies, it was reported based on the linkage with a PYGM (muscle glycogen phosphorylase gene) marker that a gene participating in the onset of MEN1 existed in the long arm of chromosome 11 [Larsson et al., *Nature*, **332**, 85 - 87 (1988)]. Subsequently, it was reported that it existed in a region of 12cM located between D11S149 maker and INT2 marker of 11q13 [Nakamura et al., *Am. J. Hum. Genet.*, **44**, 751 - 755 (1989)]. We prepared a cosmid library from a Chinese hamster/human hybrid cell line containing a single human chromosome 11 and screened cosmid clones containing a part of the human chromosomal DNA with the use of a whole human DNA as probe [Tokino et al., *Am. J. Hum. Genet.*, **48**, 258 - 268 (1991); and Tanigami et al., *Am. J. Hum. Genet.*, **50**, 56 - 64 (1992)]. Then, these clones were tested by hybridization with a hybrid cell line panel containing a part of human chromosome 11 [Tanigami et al., *Am. J. Hum. Genet.*, **50**, 56 - 64 (1992)] and were mapped on the chromosome through the fluorescent in-situ hybridization (FISH) method [Hori et al., *Genomics*, **13**, 129 - 133 (1992)]. By effecting the linkage analysis with the use of the cosmid markers whereby RFLP could be detected, the location of the MEN1 gene was restricted to a region of 8cM between D11S480 (cCI11-319) and D11S546 (cCI11-363) on q13 of chromosome 11 [Fujimori et al., *Am. J. Hum. Genet.*, **50**, 399 - 403 (1992)] (see Fig. 1).

### 35 Example 2 Preparation of deletion map of chromosome 11 in MEN1-associated tumors

On the other hand, investigations on the loss of heterozygosity (LOH) of the chromosome 11 in MEN1-associated tumors have also suggested that the tumor suppressor gene exists in the above-mentioned region [Friedman et al., *N. Engl. J. Med.*, **321**, 213 - 218 (1989); Thakker et al., *N. Engl. J. Med.*, **321**, 218 - 224 (1989); and Bale et al., *Cancer Res.*, **51**, 1154 - 1157 (1991)]. It has been further pointed out by the mapping of the deleted region on chromosome 11q in these tumors that the MEN1 gene exists in the telomere side of PYGM [Bystroen et al., *Proc. Nat. Acad. Sci. USA*, **87**, 1968 - 1972 (1990)]. The results of the examination on LOH are arranged together with the results of the linkage analysis and it is thus considered that the MEN1 gene exists in a region of about 3cM between PYGM and D11S546 (see Fig. 1).

### 45 Example 3 Preparation of physical map of 11q13 region

We cleaved human genomic DNA with 8 restriction enzymes each having a rare breakage point. After separating DNA fragments by the pulse field gel electrophoresis, the Southern blotting analysis was carried out by using more than 50 cosmid clones existing in 11q13 as probes. Thus, the relationship in locations among the cosmid clones has been clarified depending upon the capability of each clone of being hybridized with a common genomic DNA fragment. As a result, it has been found out that cCI11-4, cCI11-367, cCI11-364, cCI11-247, cCI11-363, cCI11-254 and PYGM can be hybridized with genomic DNA fragments relating to one another and thus they are located within a range of about 1 Mb in the telomere side of PYGM [Tanigami et al., *Genomics*, **13**, 21 - 24 (1992)]. It has been suggested that PYGM and cCI11-4, among these cosmid clones, are markers closest to the MEN1 gene (lod values: 5.03 and 5.13) [Fujimori et al., *Am. J. Hum. Genet.*, **50**, 399 - 403 (1992)]. Based on the results of the mapping of the breakage points with restriction enzymes in YAC clones 1908F2 and 199A7 isolated by using PYGM as a probe, it has been clarified that cCI11-367, among the 6 cosmid clones as described above, is also close to PYGM.

## Example 4 Isolation of exon sequence from 11q13 region

As described above, cCI11-4 and cCI11-367 are cosmid clones which are closest to the MEN1 gene. Thus, an attempt was made to isolate exons from these 2 cosmid clones by the exon trapping method [Buckler, A., et al., Proc. Natl. Acad. Sci. USA, **88**, 4005 - 4009 (1991)]. The cosmid DNA was cleaved with BglII or BamHI, or both of these enzymes, and the fragment thus obtained was linked to the BamHI site of an exon splicing vector pSPL1. Transfection into COS-7 cells and isolation of exon sequences by the reverse transcription PCR (RT-PCR) were effected each in accordance with the procedure described in the original paper. Consequently, 3 exon sequences originating in cCI11-367 were obtained and named respectively s367E1, s367E2 and s367E4. These exon sequences were respectively in sizes of 147 bp, 76 bp and 129 bp.

## Example 5 Isolation of full-length cDNA

By using s367E4 (i.e., one of the exon sequences obtained in the above Example 4) as probe, a human cortical cDNA library was screened. Thus, a clone AB1 carrying a cDNA insert of 1 kb was obtained. With the use of this clone AB1 as a probe, further, a cDNA clone FL2 was obtained from a human fetal liver cDNA library while cDNA clones CE5, CE9 and CE16 were obtained from a human cerebellar cDNA library. Then, it was confirmed that each of these clones could be hybridized with the original cosmid clone cCI11-367 and mapped on the chromosome 11q13 with a hybrid cell line panel. A sequence constructed by overlapping these cDNA clones one another at the common parts corresponded to ZFM1 cDNA of 3200 bp (SEQ ID NO:1). This ZFM1 cDNA contained an open reading frame (ORF) of 1869 bp which corresponded to a sequence of base Nos. 383 to 2251 in SEQ ID NO:1. Based on the information as will be described hereinbelow, it has been proved that the sequence of SEQ ID NO: 1 and that of each clone can be regarded as being composed of 6 domains A (base Nos. 1 to 413 in SEQ ID NO:1), B (base Nos. 414 to 542 in SEQ ID NO:1), C (base Nos. 543 to 618 in SEQ ID NO:1), D (base Nos. 619 to 1964 in SEQ ID NO:1), E (base Nos. 1965 to 2218 in SEQ ID NO:1) and F (base Nos. 2219 to 3200 in SEQ ID NO:1) and domains G and H which are completely different therefrom. Namely, the exon sequences s367E2 and s367E4 obtained in the above Example 4 corresponded respectively to the domains C and B. The cDNA clone CE5 lacked in a domain E consisting of 254 base pairs corresponding to a sequence of base Nos. 1965 to 2218 in SEQ ID NO:1, which may be due to an alternative splicing. The cDNA clone AB1 contained domains A and B and the different one G but not the domains C, D, E and F. The cDNA clone CE16 consisted of the domains D and E and the different one H (see Fig. 2).

## Example 6 Characteristics of the structure of protein coded for by the tumor suppressor gene

A protein coded for by ZFM1 cDNA consisted of 623 amino acid residues and had a nuclear localizing signal containing basic amino acids in the N-terminal side. Further, a sequence C-X2-C-X4-H-X4-C (amino acid Nos. 279 - 292) had characteristics of a zinc finger motif existing in a DNA binding protein. 118 proline residues were contained in this ZFM1 protein. In particular, 69 proline residues were contained in a region of amino acid Nos. 420 to 623 thereof. The sequence of this region showed high homologies with Wilms' tumor suppressor gene product (WT1) [Gessler et al., Nature, **343**, 774 - 778 (1990)] and early growth response 2 (EGR2) protein as a transcriptional factor (27.3% and 24.0%, respectively) (see Fig. 3). WT1 is a transcription factor having a Kruppel-like zinc finger motif [Rosenberg et al., Nature, **319**, 336 - 339 (1986)]. EGR2 is a human homologue of an early growth response gene Krox-20 [Chavrier et al., EMBO J., **7**, 29 - 35 (1988)] which is expressed at the G0-G1 junction in the cell cycle of cultured mouse cells and it is also a transcriptional factor [Joseph et al., Proc. Natl. Acad. Sci. USA, **85**, 7164 - 7168 (1988)]. The ZFM1 protein further had 7 proline repetitive sequences (each consisting of at least 4 proline residues located continuously) in the C-terminal side. One of these repetitive sequences followed a glutamine repetitive sequence and thus formed a structure which was almost the same as that of the hinge domain of a mineralocorticoid receptor [Arriza et al., Science, **237**, 268 - 275 (1987)]. Such a hinge structure is essentially required in the communication between a hormone binding domain and a DNA binding domain [Krust et al., EMBO J., **5**, 891 - 897 (1986); and Giguere et al., Cell, **46**, 645 - 652 (1986)]. Further, mRNAs of a number of types originating in the ZFM1 gene were expressed in hormone-producing organs such as pancreas, thyroid, adrenal gland and ovarium (see Table 1 in Example 8).

These facts indicate that the ZFM1 protein is a tumor suppressor gene which is localized in the nuclei and exerts its function by binding to DNA and thus suppressing the proliferation of cells and that ZFM1 is a gene which participates in the onset of MEN1.

## Example 7 Structure of genomic gene

Based on the cosmid clone containing the ZFM1 gene, the genomic structure of the ZFM1 gene was determined. The ZFM1 gene existed over a region of about 20 kb in the genomic DNA and consisted of 14 exons (see Fig. 4). As Fig. 4 shows, it has been revealed that these exons (Nos. 1 to 14) and the domains A to H described in the above Exam-

ple 6 relate to each other as follows: domain A = exon 1, domain B = exon 2, domain C = exon 3, domain D = exon 4, 5, 6, 7, 8, 9, 10, 11 and 12, domain E = exon 13 and a part of exon 14, domain F = a part of exon 14, domain G = exon 2a, and domain H = exon 3a.

The sequence of SEQ ID NO: 1 contains all of these 14 exons except the exons 2a and 3a. The sequence of the cDNA clone CES consisting of the domains D-F lacks in the domain E corresponding to the exon 13 and a part of the exon 14. On the other hand, the domain G of the cDNA clone AB1 consisting of the domains A-B-G is coded for by the exon 2a which directly follows the exon 2 coding for the domain B. Also, the domain H of the cDNA clone CE16 consisting of the domains H-D-E is coded for by the exon 3a which is located immediately before the exon 4 coding for the domain D.

#### Example 8 Expression of ZFM1 gene in human tissues

By using an insert of the cDNA clone FL2 as a probe, mRNAs of various tissues were analyzed by the Northern blotting method. As a result, the expressions of ZFM1 mRNAs of 3.3 kb and 2.7 kb were observed in all of these tissues. It is considered that the larger mRNA corresponds to the full length cDNA containing the domains A-B-C-D-E-F, while the smaller mRNA corresponds to one containing the domain H instead of the domains A-B-C (see Fig. 2). To examine the expression of the ZFM1 gene in greater detail, the reverse transcription PCR (RT-PCR) analysis was effected by extracting RNAs from various human tissues and using primer sets (see the arrow heads in Fig. 2) specific for the respective domains. As a result, the expressions of ZFM1 mRNAs of various types, which were thought to be due to differences in splicing, were observed over a wide range of tissues. The expressions of 3 mRNAs having structures of A-B-C-D, A-B-G and H-D (see Fig. 2) were observed in nearly all tissues, though the expression yields differed from one another. In contrast, the expression of a mRNA having the domain E was restricted to heart, pancreas, thyroid and ovarium (see Table 1).



Table 1  
Tissue-specific expression of ZFM1

Domains	ovarium	adrenal gland	thyroid	kidney	colon	pancreas	liver	lung	heart	cerebellum	cerebrum
ABCD	+	+	+	+	+	+	+	+	+	+	+
ABG	+	+	+	+	+	+	+	+	+	+	+
HD	+	+	+	+	+	+	+	+	+	+	+
DEF	+	+	+	+	+	+	+	+	+	+	+
DF <sub>1</sub>	+	+	+	+	+	+	+	+	+	+	+

SEQUENCE LISTING

(2) INFORMATION FOR SEQ ID NO: 1:

(1) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 3200 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(11) MOLECULE TYPE: cDNA

(v1) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(1x) FEATURE:

(A) FEATURE KEY: 5'UTR

(B) LOCATION: 1..382

(A) FEATURE KEY: CDS

(B) LOCATION: 383..2254

(A) FEATURE KEY: exon 1

(B) LOCATION: 1..413

(A) FEATURE KEY: exon 2

(B) LOCATION: 414..542

(A) FEATURE KEY: exon 3

(B) LOCATION: 543..618

(A) FEATURE KEY: exon 4

(B) LOCATION: 619..771

(A) FEATURE KEY: exon 5

(B) LOCATION: 772..861

EP 0 727 486 A2

5 (A) FEATURE KEY: exon 6  
 (B) LOCATION: 862..1045  
 (A) FEATURE KEY: exon 7  
 10 (B) LOCATION: 1046..1161  
 (A) FEATURE KEY: exon 8  
 (B) LOCATION: 1162..1269  
 15 (A) FEATURE KEY: exon 9  
 (B) LOCATION: 1270..1450  
 20 (A) FEATURE KEY: exon 10  
 (B) LOCATION: 1451..1724  
 (A) FEATURE KEY: exon 11  
 25 (B) LOCATION: 1725..1784  
 (A) FEATURE KEY: exon 12  
 30 (B) LOCATION: 1785..1964  
 (A) FEATURE KEY: exon 13  
 35 (B) LOCATION: 1965..2137  
 (A) FEATURE KEY: exon 14  
 (B) LOCATION: 2138..3132  
 40 (A) FEATURE KEY: 3'UTR  
 (B) LOCATION: 2280..3200

(x1) SEQUENCE DESCRIPTION: SEQ ID NO:1:

45 CGTTGCTGTC GAAATGAAGT GCGCGCTGCG ACACCTCCCA GCCCACCAGAA CTCCGCCGCC 60  
 ATTCCTCGC TTGCCTAACG GTTCGGCCAA TCCCAGCGCG CATCAATGCC GGA CTGAGGC 120  
 50 TCCGCCAATC GGAGGCGGCC GATTCGACC CTTCGCCTCG GCCCGGCCCA ATCCATTCCC 180  
 CGGCCCCGCC GCCCCGGGCC CGCCCCGCG GTGCCCTCTC TCCTCCCTCT TTGTGCGTCT 240

55

EP 0 727 486 A2

CGCGCCGCGG CCGCCGCGCG CGTGAGAGGA CGGGCTCCGC GCGCTCCGGC AGCGCATTCG 300  
5 GGTCCCCTCC CCCCGGGAGG CTTGCGAAGG AGAAGCCGCC GCAGAGGAAA AGCAGGTGCC 360  
GGTGCCTGTC CCCGGGGGCG CC ATG GCG ACC GGA GCG AAC GCC ACG CCG TTG 412  
10 Met Ala Thr Gly Ala Asn Ala Thr Pro Leu  
1 5 10  
GAC TTC CCA AGT AAG AAG CGG AAG AGG AGC CGC TGG AAC CAA GAC ACA 460  
15 Asp Phe Pro Ser Lys Lys Arg Lys Arg Ser Arg Trp Asn Gln Asp Thr  
15 20 25  
20 ATG GAA CAG CCG ACA GTG ATT CCA GGA ATG CCT ACA GTT ATT CCC CCT 508  
Met Glu Gln Pro Thr Val Ile Pro Gly Met Pro Thr Val Ile Pro Pro  
30 35 40  
25 GGA CTT ACT CGA GAA CAA GAA AGA GCT TAT ATA GTG CAA CTG CAG ATA 556  
Gly Leu Thr Arg Glu Gln Glu Arg Ala Tyr Ile Val Gln Leu Gln Ile  
30 45 50 55  
GAA GAC CTG ACT CGT AAA CTG CGC ACA GGG GAC CTG GGC ATC CCC CCT 604  
35 Glu Asp Leu Thr Arg Lys Leu Arg Thr Gly Asp Leu Gly Ile Pro Pro  
60 65 70  
AAC CCT GAG GAC AGG TCC CCT TCC CCT GAG CCC ATC TAC AAT AGC GAG 652  
40 Asn Pro Glu Asp Arg Ser Pro Ser Pro Glu Pro Ile Tyr Asn Ser Glu  
75 80 85 90  
45 GGG AAG CGG CTT AAC ACC CGA GAG TTC CGC ACC CGC AAA AAG CTG GAA 700  
Gly Lys Arg Leu Asn Thr Arg Glu Phe Arg Thr Arg Lys Lys Leu Glu  
95 100 105  
50  
55

EP 0 727 486 A2

	GAG GAG CGG CAC AAC CTC ATC ACA GAG ATG GTT GCA CTC AAT CCG GAT	748
5	Glu Glu Arg His Asn Leu Ile Thr Glu Met Val Ala Leu Asn Pro Asp	
	110 115 120	
10	TTC AAG CCA CCT GCA GAT TAC AAA CCT CCA GCA ACA CGT GTG AGT GAT	796
	Phe Lys Pro Pro Ala Asp Tyr Lys Pro Pro Ala Thr Arg Val Ser Asp	
	125 130 135	
15	AAA GTC ATG ATT CCA CAA GAT GAG TAC CCA GAA ATC AAC TTT GTG GGG	844
	Lys Val Met Ile Pro Gln Asp Glu Tyr Pro Glu Ile Asn Phe Val Gly	
	140 145 150	
20	CTG CTC ATC GGG CCC AGA GGG AAC ACC CTG AAG AAC ATA GAG AAG GAG	892
	Leu Leu Ile Gly Pro Arg Gly Asn Thr Leu Lys Asn Ile Glu Lys Glu	
25	155 160 165 170	
	TGC AAT GCC AAG ATT ATG ATC CGG GGG AAA GGG TCT GTG AAA GAA GGG	940
30	Cys Asn Ala Lys Ile Met Ile Arg Gly Lys Gly Ser Val Lys Glu Gly	
	175 180 185	
35	AAG GTT GGG CGC AAA GAT GGC CAG ATG TTG CCA GGA GAA GAT GAG CCA	988
	Lys Val Gly Arg Lys Asp Gly Gln Met Leu Pro Gly Glu Asp Glu Pro	
	190 195 200	
40	CTT CAT GCC CTG GTT ACT GCC AAT ACA ATG GAG AAC GTC AAA AAG GCA	1036
	Leu His Ala Leu Val Thr Ala Asn Thr Met Glu Asn Val Lys Lys Ala	
	205 210 215	
45	GTG GAA CAG ATA AGA AAC ATC CTG AAG CAG GGT ATC GAG ACT CCA GAG	1084
	Val Glu Gln Ile Arg Asn Ile Leu Lys Gln Gly Ile Glu Thr Pro Glu	
50	220 225 230	
55		

EP 0 727 486 A2

	GAC CAG AAT GAT CTA CGG AAG ATG CAG CTT CGG GAG TTG GCT CGC TTA	1132
5	Asp Gln Asn Asp Leu Arg Lys Met Gln Leu Arg Glu Leu Ala Arg Leu	
	235                      240                      245                      250	
10	AAT GGG ACC CTT CGG GAA GAC GAT AAC AGG ATC TTA AGA CCC TGG CAG	1180
	Asn Gly Thr Leu Arg Glu Asp Asp Asn Arg Ile Leu Arg Pro Trp Gln	
	255                      260                      265	
15	AGC TCA GGG ACC CGC AGC ATT ACC AAC ACC ACA GTG TGT ACC AAG TGT	1228
	Ser Ser Gly Thr Arg Ser Ile Thr Asn Thr Thr Val Cys Thr Lys Cys	
20	270                      275                      280	
	GGA GGG GCT GGC CAC ATT GCT TCA GAC TGT AAA TTC CAA AGG CCT GGT	1276
	Gly Gly Ala Gly His Ile Ala Ser Asp Cys Lys Phe Gln Arg Pro Gly	
25	285                      290                      295	
	GAT CCT CAG TCA GCT CAG GAT AAA GCA CGG ATG GAT AAA GAA TAT TTG	1324
30	Asp Pro Gln Ser Ala Gln Asp Lys Ala Arg Met Asp Lys Glu Tyr Leu	
	300                      305                      310	
35	TCC CTC ATG GCT GAA CTG GGT GAA GCA CCT GTC CCA GCA TCT GTG GGC	1372
	Ser Leu Met Ala Glu Leu Gly Glu Ala Pro Val Pro Ala Ser Val Gly	
	315                      320                      325                      330	
40	TCC ACC TCT GGG CCT GCC ACC ACA CCC CTG GCC AGC GCA CCT CGT CCT	1420
	Ser Thr Ser Gly Pro Ala Thr Thr Pro Leu Ala Ser Ala Pro Arg Pro	
	335                      340                      345	
45	GCT GCT CCC GCC AAC AAC CCA CCT CCA CCG TCT CTC ATG TCT ACC ACC	1468
	Ala Ala Pro Ala Asn Asn Pro Pro Pro Pro Ser Leu Met Ser Thr Thr	
50	350                      355                      360	
55		

EP 0 727 486 A2

5 CAG AGC CGC CCA CCC TGG ATG AAT TCT GGT CCT TCA GAG AGT TGG CCC 1516  
 Gln Ser Arg Pro Pro Trp Met Asn Ser Gly Pro Ser Glu Ser Trp Pro  
 365 370 375  
 10 TAC CAC GGC ATG CAT GGA GGT GGT CCT GGT GGG CCC GGA GGT GGC CCC 1564  
 Tyr His Gly Met His Gly Gly Gly Pro Gly Gly Pro Gly Gly Gly Pro  
 380 385 390  
 15 CAC AGC TTC CCA CAC CCA TTA CCC AGC CTG ACA GGT GGG CAT GGT GGA 1612  
 His Ser Phe Pro His Pro Leu Pro Ser Leu Thr Gly Gly His Gly Gly  
 20 395 400 405 410  
 CAT CCC ATG CAG CAC AAC CCC AAT GGA CCC CCA CCC CCT TGG ATG CAG 1660  
 His Pro Met Gln His Asn Pro Asn Gly Pro Pro Pro Pro Trp Met Gln  
 25 415 420 425  
 CCA CCA CCA CCA CCG ATG AAC CAG GGC CCC CAC CCT CCT GGG CAC CAT 1708  
 30 Pro Pro Pro Pro Pro Met Asn Gln Gly Pro His Pro Pro Gly His His  
 430 435 440  
 35 GGC CCT CCT CCA ATG GAT CAG TAC CTG GGA AGT ACG CCT GTG GGC TCT 1756  
 Gly Pro Pro Pro Met Asp Gln Tyr Leu Gly Ser Thr Pro Val Gly Ser  
 445 450 455  
 40 GGG GTC TAT CGC CTG CAT CAA GGA AAA GGT ATG ATG CCG CCA CCA CCT 1804  
 Gly Val Tyr Arg Leu His Gln Gly Lys Gly Met Met Pro Pro Pro Pro  
 45 460 465 470  
 ATG GGC ATG ATG CCG CCG CCG CCG CCT CCC AGT GGG CAG CCC CCA 1852  
 Met Gly Met Met Pro Pro Pro Pro Pro Pro Pro Ser Gly Gln Pro Pro  
 50 475 480 485 490  
 55

EP 0 727 486 A2

	CCC CCT CCC TCT GGT CCT CTT CCC CCA TGG CAA CAA CAG CAG CAG CAG	1900
5	Pro Pro Pro Ser Gly Pro Leu Pro Pro Trp Gln Gln Gln Gln Gln Gln	
	495 500 505	
10	CCT CCG CCA CCC CCT CCG CCC AGC AGC AGT ATG GCT TCC AGT ACC CCC	1948
	Pro Pro Pro Pro Pro Pro Pro Ser Ser Ser Met Ala Ser Ser Thr Pro	
	510 515 520	
15	TTG CCA TGG CAG CAA AAT ACG ACG ACT ACC ACC ACG AGC GCT GGC ACA	1996
	Leu Pro Trp Gln Gln Asn Thr Thr Thr Thr Thr Thr Ser Ala Gly Thr	
20	525 530 535	
	GGG TCC ATC CCG CCA TGG CAA CAG CAG CAG GCG GCT GCC GCA GCT TCT	2044
	Gly Ser Ile Pro Pro Trp Gln Gln Gln Gln Ala Ala Ala Ala Ala Ser	
25	540 545 550	
	CCA GGA GCC CCT CAG ATG CAA GGC AAC CCC ACT ATG GTG CCC CTG CCC	2092
30	Pro Gly Ala Pro Gln Met Gln Gly Asn Pro Thr Met Val Pro Leu Pro	
	555 560 565 570	
35	CCC GGG GTC CAG CCG CCT CTG CCG CCT GGG GCC CCT CCC CCT CCG CCC	2140
	Pro Gly Val Gln Pro Pro Leu Pro Pro Gly Ala Pro Pro Pro Pro Pro	
	575 580 585	
40	CGT AGC ATC GAG TGT CTT CTT TGT CTT CTT TCT CTC CTC ACC CAA CTC	2188
	Arg Ser Ile Glu Cys Leu Leu Cys Leu Leu Ser Leu Leu Thr Gln Leu	
45	590 595 600	
	CCT TTG CCT CTC CCC AAA CCG GGC CGC CAG GAT CCC TCC CCG CGG CGG	2236
	Pro Leu Pro Leu Pro Lys Pro Gly Arg Gln Asp Pro Ser Pro Arg Arg	
50	605 610 615	
55		



EP 0 727 486 A2

CGA TGG CCC GAG CCA TGAGAGTGAG GACTTTCGCG GCCCATTGGT GACCCTTCCA 2291  
 5 Arg Trp Pro Glu Pro  
 620 623  
 10 GGCAGACAGC CTCAGCAACG CCCCTGGTGG ACAGGATGGT TCGGCAAAGC AGCCTGAGTT 2351  
 ATTTTGTGG ACGGAATCGG AACACGCTGG CTCCATATCG TGAAATTTTT ATTAATTTTT 2411  
 TTCTTTTCC TTTGTTACTT CTTTATCTTT TCCTTTCTTC AGACTCCGTC CAAAGGAGATG 2471  
 15 CTCTCCCCGG TCTTCTGCTG CAATTAGAT TCCTTTGGGT TCTCTCCAGT TCTCCTTCCC 2531  
 TTACCAAGGA GAGGGGAGCA AATGGTTTTG GGCAAGGGCT TTGGCCATTC ATGTCAAGCT 2591  
 20 GGTGTGGGT TTTTCAAGGT GCCATAGCCA CCCCCAAATA TGTTTGTTTA AAGCGTGGGG 2651  
 TTTTTAATC TCTGCCACCC TTGTCAAGGG AGTCTGTAA AGTTGCCGAG GGTAGGTTCA 2711  
 TCTCCAGGT TCGGGATTCC CATCCGTCCT GCGATCCTG CCAGCAGTGG GTGGGCAGCC 2771  
 25 TGAGCTCCCT CGGGCTCGCC TGCCAGCCTG GAGTCTTCC TGTGCTCCTT GATCACCTGA 2831  
 GCTGCCTCAG ATTCCATTTG GTCCTCTCCT TCCTGGAAGG CTTCTTTTA TGTTTTGT 2891  
 30 TAATCCCAA TGTCTGAATG TTTTGCAGTG TGTAGGGTT TGAGCCCCTT GTTCATTCTC 2951  
 CTTCTTTTTT CCTCCGCTT CCCTCTCCAT GAAGTGATTC TGTTGACAAT AATGTATACT 3011  
 GCGCGTTCTC TCACTGGTT,TATCTGCAGA,AATTTCTCTG GGCTTTTTTC GGTGTTAGAT 3071  
 35 TCAACACTGC GCTAAAGCGG,GGATGTTCCA,TTGAATAAAA GAGCAGTGTG GTTTTCTGGG 3131  
 AAAAAAAAAA AAAAAAAAAA,AAAAAAAAA,AAAAAAAAA AAAAAAAAAA AAAAAAAAAA 3191  
 40 AAAAAAAAAA 3200

45

50

55

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

## (i) APPLICANT:

(A) NAME: Cancer Institute  
(B) STREET: 37-1, Kamiikebukuro 1-chome,  
(C) CITY: Toshima-ku, Tokyo  
(E) COUNTRY: Japan  
(F) POSTAL CODE (ZIP): none

(A) NAME: Eisai Co., Ltd.  
(B) STREET: 6-10, Koishikawa 4-chome,  
(C) CITY: Bunkyo-ku, Tokyo  
(E) COUNTRY: JAPAN  
(F) POSTAL CODE (ZIP): 112

(ii) TITLE OF INVENTION: Tumor Suppressor Gene

(iii) NUMBER OF SEQUENCES: 2

## (iv) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk  
(B) COMPUTER: IBM PC compatible  
(C) OPERATING SYSTEM: PC-DOS/MS-DOS  
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)

## (v) CURRENT APPLICATION DATA:

APPLICATION NUMBER: EP 95101980.1

## (2) INFORMATION FOR SEQ ID NO: 1:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 3200 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

## (ix) FEATURE:

(A) NAME/KEY: 5'UTR  
(B) LOCATION:1..382

## (ix) FEATURE:

(A) NAME/KEY: CDS  
(B) LOCATION:383..2254

## (ix) FEATURE:

(A) NAME/KEY: exon 1  
(B) LOCATION:1..413

## (ix) FEATURE:

(A) NAME/KEY: exon 2  
(B) LOCATION:414..542

## (ix) FEATURE:

(A) NAME/KEY: exon 3  
(B) LOCATION:543..618

## (ix) FEATURE:

(A) NAME/KEY: exon 4  
(B) LOCATION:619..771

## (ix) FEATURE:

(A) NAME/KEY: exon 5  
(B) LOCATION:772..861

EP 0 727 486 A2

- (ix) FEATURE:  
 (A) NAME/KEY: exon 6  
 (B) LOCATION:862..1045
- (ix) FEATURE:  
 (A) NAME/KEY: exon 7  
 (B) LOCATION:1046..1161
- (ix) FEATURE:  
 (A) NAME/KEY: exon 8  
 (B) LOCATION:1162..1269
- (ix) FEATURE:  
 (A) NAME/KEY: exon 9  
 (B) LOCATION:1270..1450
- (ix) FEATURE:  
 (A) NAME/KEY: exon 10  
 (B) LOCATION:1451..1724
- (ix) FEATURE:  
 (A) NAME/KEY: exon 11  
 (B) LOCATION:1725..1784
- (ix) FEATURE:  
 (A) NAME/KEY: exon 12  
 (B) LOCATION:1785..1964
- (ix) FEATURE:  
 (A) NAME/KEY: exon 13  
 (B) LOCATION:1965..2137
- (ix) FEATURE:  
 (A) NAME/KEY: exon 14  
 (B) LOCATION:2138..3132
- (ix) FEATURE:  
 (A) NAME/KEY: 3'UTR  
 (B) LOCATION:2280..3200

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

CGTTGCTGTC GAAATGAAGT GCGCGCTGCG ACACCTCCCA GCCCACCAGAA CTCCGCCGCC 60

ATTCCTCGC TTGCCTAACG GTTCGGCCAA TCCAGCGCG CATCAATGCC GGACTGAGGC 120

TCCGCCAATC GGAGGCCGCC GATTCGACC CTTGCTCTCG GCCCGGCCCA ATCCATTCCC 180

CGGCCCGGCC GCCCGCGGCC CGCCCCGCG GTGCCCTCTC TCCTCCCTCT TTGTGCGTCT 240

CGCGCCGCCG CCGCCCCCGG CGTGAGAGGA CGGGCTCCGC GCGCTCCGGC AGCGCATTCG 300

GGTCCCCTCC CCCCGGGAGG CTTGCGAAGG AGAAGCCGCC GCAGAGGAAA AGCAGGTGCC 360

GGTGCCTGTC CCCGGGGGCG CC ATG GCG ACC GGA GCG AAC GCC ACG CCG TTG 412

Met Ala Thr Gly Ala Asn Ala Thr Pro Leu  
 1 5 10

GAC TTC CCA AGT AAG AAG CGG AAG AGG AGC CGC TGG AAC CAA GAC ACA 460

Asp Phe Pro Ser Lys Lys Arg Lys Arg Ser Arg Trp Asn Gln Asp Thr  
 15 20 25

EP 0 727 486 A2

5	ATG GAA CAG CCG ACA GTG ATT CCA GGA ATG CCT ACA GTT ATT CCC CCT Met Glu Gln Pro Thr Val Ile Pro Gly Met Pro Thr Val Ile Pro Pro 30 35 40	308
10	GGA CTT ACT CGA GAA CAA GAA AGA GCT TAT ATA GTG CAA CTG CAG ATA Gly Leu Thr Arg Glu Gln Glu Arg Ala Tyr Ile Val Gln Leu Gln Ile 45 50 55	556
15	GAA GAC CTG ACT CGT AAA CTG CGC ACA GGG GAC CTG GGC ATC CCC CCT Glu Asp Leu Thr Arg Lys Leu Arg Thr Gly Asp Leu Gly Ile Pro Pro 60 65 70	604
20	AAC CCT GAG GAC AGG TCC CCT TCC CCT GAG CCC ATC TAC AAT AGC GAG Asn Pro Glu Asp Arg Ser Pro Ser Pro Glu Pro Ile Tyr Asn Ser Glu 75 80 85 90	652
25	GGG AAG CGG CTT AAC ACC CGA GAG TTC CGC ACC CGC AAA AAG CTG GAA Gly Lys Arg Leu Asn Thr Arg Glu Phe Arg Thr Arg Lys Lys Leu Glu 95 100 105	700
30	GAG GAG CGG CAC AAC CTC ATC ACA GAG ATG GTT GCA CTC AAT CCG GAT Glu Glu Arg His Asn Leu Ile Thr Glu Met Val Ala Leu Asn Pro Asp 110 115 120	748
35	TTC AAG CCA CCT GCA GAT TAC AAA CCT CCA GCA ACA CGT GTG AGT GAT Phe Lys Pro Pro Ala Asp Tyr Lys Pro Pro Ala Thr Arg Val Ser Asp 125 130 135	796
40	AAA GTC ATG ATT CCA CAA GAT GAG TAC CCA GAA ATC AAC TTT GTG GGG Lys Val Met Ile Pro Gln Asp Glu Tyr Pro Glu Ile Asn Phe Val Gly 140 145 150	844
45	CTG CTC ATC GGG CCC AGA GGG AAC ACC CTG AAG AAC ATA GAG AAG GAG Leu Leu Ile Gly Pro Arg Gly Asn Thr Leu Lys Asn Ile Glu Lys Glu 155 160 165 170	892
50	TGC AAT GCC AAG ATT ATG ATC CGG GGG AAA GGG TCT GTG AAA GAA GGG Cys Asn Ala Lys Ile Met Ile Arg Gly Lys Gly Ser Val Lys Glu Gly 175 180 185	940
55	AAG GTT GGG CGC AAA GAT GGC CAG ATG TTG CCA GGA GAA GAT GAG CCA Lys Val Gly Arg Lys Asp Gly Gln Met Leu Pro Gly Glu Asp Glu Pro 190 195 200	988
60	CTT CAT GCC CTG GTT ACT GCC AAT ACA ATG GAG AAC GTC AAA AAG GCA Leu His Ala Leu Val Thr Ala Asn Thr Met Glu Asn Val Lys Lys Ala 205 210 215	1036
65	GTG GAA CAG ATA AGA AAC ATC CTG AAG CAG GGT ATC GAG ACT CCA GAG Val Glu Gln Ile Arg Asn Ile Leu Lys Gln Gly Ile Glu Thr Pro Glu 220 225 230	1084
70	GAC CAG AAT GAT CTA CGG AAG ATG CAG CTT CGG GAG TTG GCT CGC TTA Asp Gln Asn Asp Leu Arg Lys Met Gln Leu Arg Glu Leu Ala Arg Leu 235 240 245 250	1132
75	AAT GGG ACC CTT CGG GAA GAC GAT AAC AGG ATC TTA AGA CCC TGG CAG Asn Gly Thr Leu Arg Glu Asp Asp Asn Arg Ile Leu Arg Pro Trp Gln 255 260 265	1180
80	AGC TCA GGG ACC CGC AGC ATT ACC AAC ACC ACA GTG TGT ACC AAG TGT Ser Ser Gly Thr Arg Ser Ile Thr Asn Thr Thr Val Cys Thr Lys Cys 270 275 280	1228
85	GGA GGG GCT GGC CAC ATT GCT TCA GAC TGT AAA TTC CAA AGG CCT GGT	1276

EP 0 727 486 A2

	Gly	Gly	Ala	Gly	His	Ile	Ala	Ser	Asp	Cys	Lys	Phe	Gln	Arg	Pro	Gly	
			285					290					295				
5	GAT	CCT	CAG	TCA	GCT	CAG	GAT	AAA	GCA	CGG	ATG	GAT	AAA	GAA	TAT	TTG	1324
	Asp	Pro	Gln	Ser	Ala	Gln	Asp	Lys	Ala	Arg	Met	Asp	Lys	Glu	Tyr	Leu	
		300					305					310					
	TCC	CTC	ATG	GCT	GAA	CTG	GGT	GAA	GCA	CCT	GTC	CCA	GCA	TCT	GTG	GGC	1372
	Ser	Leu	Met	Ala	Glu	Leu	Gly	Glu	Ala	Pro	Val	Pro	Ala	Ser	Val	Gly	
		315				320					325					330	
10	TCC	ACC	TCT	GGG	CCT	GCC	ACC	ACA	CCC	CTG	GCC	AGC	GCA	CCT	CGT	CCT	1420
	Ser	Thr	Ser	Gly	Pro	Ala	Thr	Thr	Pro	Leu	Ala	Ser	Ala	Pro	Arg	Pro	
					335					340					345		
	GCT	GCT	CCC	GCC	AAC	AAC	CCA	CCT	CCA	CCG	TCT	CTC	ATG	TCT	ACC	ACC	1468
15	Ala	Ala	Pro	Ala	Asn	Asn	Pro	Pro	Pro	Ser	Leu	Met	Ser	Thr	Thr		
				350					355					360			
	CAG	AGC	CGC	CCA	CCC	TGG	ATG	AAT	TCT	GGT	CCT	TCA	GAG	AGT	TGG	CCC	1516
	Gln	Ser	Arg	Pro	Pro	Trp	Met	Asn	Ser	Gly	Pro	Ser	Glu	Ser	Trp	Pro	
			365					370					375				
20	TAC	CAC	GGC	ATG	CAT	GGA	GGT	GGT	CCT	GGT	GGG	CCC	GGA	GGT	GGC	CCC	1564
	Tyr	His	Gly	Met	His	Gly	Gly	Gly	Pro	Gly	Gly	Pro	Gly	Gly	Gly	Pro	
		380					385					390					
	CAC	AGC	TTC	CCA	CAC	CCA	TTA	CCC	AGC	CTG	ACA	GGT	GGG	CAT	GGT	GGA	1612
25	His	Ser	Phe	Pro	His	Pro	Leu	Pro	Ser	Leu	Thr	Gly	Gly	His	Gly	Gly	
		395				400					405					410	
	CAT	CCC	ATG	CAG	CAC	AAC	CCC	AAT	GGA	CCC	CCA	CCC	CCT	TGG	ATG	CAG	1660
	His	Pro	Met	Gln	His	Asn	Pro	Asn	Gly	Pro	Pro	Pro	Pro	Trp	Met	Gln	
					415				420						425		
30	CCA	CCA	CCA	CCA	CCG	ATG	AAC	CAG	GGC	CCC	CAC	CCT	CCT	GGG	CAC	CAT	1708
	Pro	Pro	Pro	Pro	Pro	Met	Asn	Gln	Gly	Pro	His	Pro	Pro	Gly	His	His	
					430				435					440			
	GGC	CCT	CCT	CCA	ATG	GAT	CAG	TAC	CTG	GGA	AGT	ACG	CCT	GTG	GGC	TCT	1756
	Gly	Pro	Pro	Pro	Met	Asp	Gln	Tyr	Leu	Gly	Ser	Thr	Pro	Val	Gly	Ser	
					445			450					455				
35	GGG	GTC	TAT	CGC	CTG	CAT	CAA	GGA	AAA	GGT	ATG	ATG	CCG	CCA	CCA	CCT	1804
	Gly	Val	Tyr	Arg	Leu	His	Gln	Gly	Lys	Gly	Met	Met	Pro	Pro	Pro	Pro	
		460					465					470					
	ATG	GGC	ATG	ATG	CCG	CCG	CCG	CCG	CCG	CCT	CCC	AGT	GGG	CAG	CCC	CCA	1852
40	Met	Gly	Met	Met	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Ser	Gly	Gln	Pro	Pro	
		475				480						485				490	
	CCC	CCT	CCC	TCT	GGT	CCT	CTT	CCC	CCA	TGG	CAA	CAA	CAG	CAG	CAG	CAG	1900
	Pro	Pro	Pro	Ser	Gly	Pro	Leu	Pro	Pro	Trp	Gln	Gln	Gln	Gln	Gln	Gln	
					495					500					505		
45	CCT	CCG	CCA	CCC	CCT	CCG	CCC	AGC	AGC	AGT	ATG	GCT	TCC	AGT	ACC	CCC	1948
	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Ser	Ser	Ser	Met	Ala	Ser	Ser	Thr	Pro	
					510				515					520			
	TTG	CCA	TGG	CAG	CAA	AAT	ACG	ACG	ACT	ACC	ACC	ACG	AGC	GCT	GGC	ACA	1996
50	Leu	Pro	Trp	Gln	Gln	Asn	Thr	Thr	Thr	Thr	Thr	Thr	Ser	Ala	Gly	Thr	
			525				530						535				
	GGG	TCC	ATC	CCG	CCA	TGG	CAA	CAG	CAG	CAG	GCG	GCT	GCC	GCA	GCT	TCT	2044
	Gly	Ser	Ile	Pro	Pro	Trp	Gln	Gln	Gln	Gln	Ala	Ala	Ala	Ala	Ala	Ser	
		540					545					550					

55

EP 0 727 486 A2

5	CCA GGA GCC CCT CAG ATG CAA GGC AAC CCC ACT ATG GTG CCC CTG CCC Pro Gly Ala Pro Gln Met Gln Gly Asn Pro Thr Met Val Pro Leu Pro 555 560 565 570	2092
10	CCC GGG GTC CAG CCG CCT CTG CCG CCT GGG GCC CCT CCC CCT CCG CCC Pro Gly Val Gln Pro Pro Leu Pro Pro Gly Ala Pro Pro Pro Pro Pro 575 580 585	2140
15	CGT AGC ATC GAG TGT CTT CTT TGT CTT CTT TCT CTC CTC ACC CAA CTC Arg Ser Ile Glu Cys Leu Leu Cys Leu Leu Ser Leu Leu Thr Gln Leu 590 595 600	2188
20	CCT TTG CCT CTC CCC AAA CCG GGC CGC CAG GAT CCC TCC CCG CGG CGG Pro Leu Pro Leu Pro Lys Pro Gly Arg Gln Asp Pro Ser Pro Arg Arg 605 610 615	2236
25	CGA TGG CCC GAG CCA TGA GAGTGAGGAC TTTCCGCGCC CATTGGTGAC Arg Trp Pro Glu Pro 620	2284
30	CCTTCCAGGC AGACAGCCTC AGCAACGCC CTGGTGGACA GGATGGTTCG GCAAAGCAGC CTGAGTTATT TTTGTGGACG GAATCGGAAC ACGCTGGCTC CATATCGTGA AATTTTATT AATTTTTTTC TTTTCTTTT GTTACTTCTT TATCTTTTCC TTTCTTCAGA CTCCGTCCAA GGAGATGCTC TCCCCGGTCT TCTGCTGCAA TTTAGATTCC TTTGGGTCT CTCCAGTTCT CCTTCCCTTA CCAAGGAGAG GGGAGCAAAT GGTTTTGGGC AAGGGCTTTG GCCATTCATG TCAAGCTGGT TGTGGGTTTT TCAAGGTGCC ATAGCCACCC CCAAATATGT TTGTTTAAAG CGTGGGGTTT TTTAATCTCT GCCACCTTG TCAAGGGAGT CTTGTAAAGT TGCCGAGGGT AGGTTTCATCT CCAGGTTTCG GGATTCCTCAT CCGTCTGGC GATCCTGCCA GCAGTGGGTG GGCAGCCTGA GCTCCCTCGG GCTCGCCTGC CAGCCTGGAG TTCTTCTGT GCTCCTTGAT CACCTGAGCT GCCTCAGATT CCATTTGGTC CTCTCCTTCC TGAAGGCTT CTTTTATGT TTTGTTTTAA TCCCAATGT CTGAATGTTT TGCAGTGTGT AGGGGTTTGA GCCCCTTGT CATTCTCCTT CCTTTTCTT CCCGCTTCCC TCTCCATGAA GTGATTCTGT TGACAATAAT GTATACTGCG CGTCTCTTC ACTGGTTTAT CTGCAGAAAT TTCTCTGGGC TTTTTCGGT GTTAGATTCA AACTGCGCT AAAGCGGGGA TGTTCCATTG AATAAAAGAG CAGTGTGGTT TTCTGGGAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAA AAAAAA	2344 2404 2464 2524 2584 2644 2704 2764 2824 2884 2944 3004 3064 3124 3184 3200

- (2) INFORMATION FOR SEQ ID NO: 2:
- (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 623 amino acids
    - (B) TYPE: amino acid
    - (D) TOPOLOGY: linear
  - (ii) MOLECULE TYPE: protein
  - (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

EP 0 727 486 A2

Met Ala Thr Gly Ala Asn Ala Thr Pro Leu Asp Phe Pro Ser Lys Lys  
1 5 10 15

Arg Lys Arg Ser Arg Trp Asn Gln Asp Thr Met Glu Gln Pro Thr Val  
20 25 30

Ile Pro Gly Met Pro Thr Val Ile Pro Pro Gly Leu Thr Arg Glu Gln  
35 40 45

Glu Arg Ala Tyr Ile Val Gln Leu Gln Ile Glu Asp Leu Thr Arg Lys  
50 55 60

Leu Arg Thr Gly Asp Leu Gly Ile Pro Pro Asn Pro Glu Asp Arg Ser  
65 70 75 80

Pro Ser Pro Glu Pro Ile Tyr Asn Ser Glu Gly Lys Arg Leu Asn Thr  
85 90 95

Arg Glu Phe Arg Thr Arg Lys Lys Leu Glu Glu Glu Arg His Asn Leu  
100 105 110

Ile Thr Glu Met Val Ala Leu Asn Pro Asp Phe Lys Pro Pro Ala Asp  
115 120 125

Tyr Lys Pro Pro Ala Thr Arg Val Ser Asp Lys Val Met Ile Pro Gln  
130 135 140

Asp Glu Tyr Pro Glu Ile Asn Phe Val Gly Leu Leu Ile Gly Pro Arg  
145 150 155 160

Gly Asn Thr Leu Lys Asn Ile Glu Lys Glu Cys Asn Ala Lys Ile Met  
165 170 175

Ile Arg Gly Lys Gly Ser Val Lys Glu Gly Lys Val Gly Arg Lys Asp  
180 185 190

Gly Gln Met Leu Pro Gly Glu Asp Glu Pro Leu His Ala Leu Val Thr  
195 200 205

Ala Asn Thr Met Glu Asn Val Lys Lys Ala Val Glu Gln Ile Arg Asn  
210 215 220

Ile Leu Lys Gln Gly Ile Glu Thr Pro Glu Asp Gln Asn Asp Leu Arg  
225 230 235 240

Lys Met Gln Leu Arg Glu Leu Ala Arg Leu Asn Gly Thr Leu Arg Glu  
245 250 255

Asp Asp Asn Arg Ile Leu Arg Pro Trp Gln Ser Ser Gly Thr Arg Ser  
260 265 270

Ile Thr Asn Thr Thr Val Cys Thr Lys Cys Gly Gly Ala Gly His Ile  
275 280 285

Ala Ser Asp Cys Lys Phe Gln Arg Pro Gly Asp Pro Gln Ser Ala Gln  
290 295 300

Asp Lys Ala Arg Met Asp Lys Glu Tyr Leu Ser Leu Met Ala Glu Leu  
305 310 315 320

Gly Glu Ala Pro Val Pro Ala Ser Val Gly Ser Thr Ser Gly Pro Ala  
325 330 335

Thr Thr Pro Leu Ala Ser Ala Pro Arg Pro Ala Ala Pro Ala Asn Asn  
340 345 350

EP 0 727 486 A2

Pro Pro Pro Pro Ser Leu Met Ser Thr Thr Gln Ser Arg Pro Pro Trp  
 355 360 365

5 Met Asn Ser Gly Pro Ser Glu Ser Trp Pro Tyr His Gly Met His Gly  
 370 375 380

Gly Gly Pro Gly Gly Pro Gly Gly Gly Pro His Ser Phe Pro His Pro  
 385 390 395 400

10 Leu Pro Ser Leu Thr Gly Gly His Gly Gly His Pro Met Gln His Asn  
 405 410 415

Pro Asn Gly Pro Pro Pro Pro Trp Met Gln Pro Pro Pro Pro Pro Met  
 420 425 430

15 Asn Gln Gly Pro His Pro Pro Gly His His Gly Pro Pro Pro Met Asp  
 435 440 445

Gln Tyr Leu Gly Ser Thr Pro Val Gly Ser Gly Val Tyr Arg Leu His  
 450 455 460

20 Gln Gly Lys Gly Met Met Pro Pro Pro Pro Met Gly Met Met Pro Pro  
 465 470 475 480

Pro Pro Pro Pro Pro Ser Gly Gln Pro Pro Pro Pro Pro Ser Gly Pro  
 485 490 495

25 Leu Pro Pro Trp Gln Gln Gln Gln Gln Gln Pro Pro Pro Pro Pro Pro  
 500 505 510

30 Pro Ser Ser Ser Met Ala Ser Ser Thr Pro Leu Pro Trp Gln Gln Asn  
 515 520 525

Thr Thr Thr Thr Thr Thr Ser Ala Gly Thr Gly Ser Ile Pro Pro Trp  
 530 535 540

35 Gln Gln Gln Gln Ala Ala Ala Ala Ala Ser Pro Gly Ala Pro Gln Met  
 545 550 555 560

Gln Gly Asn Pro Thr Met Val Pro Leu Pro Pro Gly Val Gln Pro Pro  
 565 570 575

40 Leu Pro Pro Gly Ala Pro Pro Pro Pro Pro Arg Ser Ile Glu Cys Leu  
 580 585 590

Leu Cys Leu Leu Ser Leu Leu Thr Gln Leu Pro Leu Pro Leu Pro Lys  
 595 600 605

45 Pro Gly Arg Gln Asp Pro Ser Pro Arg Arg Arg Trp Pro Glu Pro  
 610 615 620

Claims

1. A DNA comprising the full structure or a part of the DNA represented by SEQ ID NO:1 or a DNA essentially equal to the DNA comprising the full structure or a part of the DNA represented by SEQ ID NO:1.
2. A polypeptide comprising the full structure or a part of the polypeptide coded for by the DNA represented by SEQ ID NO:1 or a polypeptide essentially equal to the polypeptide comprising the full structure or a part of a polypeptide coded for by the DNA represented by SEQ ID NO:1.



**EP 0 727 486 A2**

3. A transformant transformed by a plasmid having, integrated therein, the full structure or a part of the DNA represented by SEQ ID NO:1 which can be expressed therein.
4. An antibody against the polypeptide as set forth in Claim 2 as an antigen.
5. A gene analysis method which comprises using, as a primer, a probe or a marker, a DNA comprising a part of the DNA represented by SEQ ID NO:1 and hybridizing the primer, the probe or the marker with a DNA to be tested.

10

15

20

25

30

35

40

45

50

55

FIG. 1




FIG. 2





FIG. 3

WT 1 105 E A S A E R L Q G R R S R G A -- S G S E P Q M G S D V R D L N A L L P A V P S L G G G G C A L P V S G A A Q W - 160  
 ZFM 1 383 G P H S F P H P L P S L T G G -- H G G H P M Q H N P N G P P P W M Q P P P P M N Q G P H -- P P G H G P P P M - 447  
 EGR 2 186 S P P P P P P P Y S G C A G D L Y Q D P S A F L S A A T T S T S S L A Y P P P P S Y P S P K -- P A T D P G L F P M I 223

WT 1 161 A P V L D F A P P G A S - A Y -- -- G S L G G P A - P P P A P P P P P P P P H S F I K Q E P S W G A E P - H E E Q 213  
 ZFM 1 448 D Q Y L G S T P V G S G - V Y R L H Q G K G M M P - P P P M G M M P P P P P P P S G - Q P P P P S G P L P P W O O Q 503  
 EGR 2 224 P D Y P G F F P S Q C Q R D L H G T A G P D R K P F P C P L D T L R V P P P L T P L - S T I R N F T L G G P S A G M T 278

FIG. 4



(19)



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11) EP 0 727 486 A3

(12)

# EUROPEAN PATENT APPLICATION

(88) Date of publication A3:  
04.12.1996 Bulletin 1996/49

(51) Int. Cl.<sup>6</sup>: C12N 15/12, C07K 14/47,  
C12N 5/10, C12P 21/08,  
C12Q 1/68

(43) Date of publication A2:  
21.08.1996 Bulletin 1996/34

(21) Application number: 95101980.1

(22) Date of filing: 14.02.1995

(84) Designated Contracting States:  
DE FR GB

(71) Applicants:  
• CANCER INSTITUTE  
Toshima-ku, Tokyo (JP)  
• Eisai Co., Ltd.  
Tokyo 112 (JP)

(72) Inventors:  
• Nakamura, Yusuke  
Yokohama-shi, Kanagawa (JP)

• Imai, Takashi  
Narashino-shi, Chiba (JP)

(74) Representative: Hansen, Bernd, Dr. Dipl.-Chem.  
et al  
Hoffmann, Eitle & Partner,  
Patentanwälte,  
Arabellastrasse 4  
81925 München (DE)

(54) Tumour suppressor gene

(57) A detailed genetic map on human chromosome 11 was prepared. Then, a commonly deleted region on the chromosome in the tumor tissues of patients with multiple endocrine neoplasia type 1 was identified. Further, by the linkage analysis on a family line with this disease, a gene causative of this disease was localized. A gene present in the region common to these observations was cloned and the structure of this gene was determined. Because a protein coded by this DNA is homologous with those of transcriptional factors, it is expected that the above-mentioned gene may be a novel tumor suppressor gene. Further, it is also expected that the above-mentioned gene and a protein coded for thereby may be useful in preparations of a remedy for cancer and a diagnostic drug for cancer.

EP 0 727 486 A3



European Patent  
Office

## EUROPEAN SEARCH REPORT

Application Number  
EP 95 10 1980

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
D,Y	PROC. NATL. ACAD. SCI. USA, vol. 88, 1991, pages 4005-4009, XP002014710 A.J. BUCKLER ET AL.: "Exon amplification; a strategy to isolate mammalian genes based on RNA splicing" *whole document*	1-5	C12N15/12 C07K14/47 C12N5/10 C12P21/08 C12Q1/68
Y	GENOMICS, vol. 13, 1992, pages 16-20, XP002014711 A. TANIGAMI ET AL.: "A 14-Mb physical map of the region at chromosome 11q13 harboring the MEN1 locus and the tumor amplicon region" *whole document, especially Results and Discussion sections*	1-5	
D,Y	PROC. NATL. ACAD. SCI. USA, vol. 87, 1990, pages 1968-1972, XP002014712 C. BYSTRÖM ET AL.: "Localization of the MEN1 gene to a small region within chromosome 11q13 by deletion mapping in tumors" *whole document*	1-5	TECHNICAL FIELDS SEARCHED (Int.Cl.6)  C12N C07K C12P C12Q
D,Y	AM. J. HUM. GENET., vol. 50, 1992, pages 399-403, XP002014713 M. FUJIMORI ET AL.: "Fine-scale mapping of the gene responsible for multiple endocrine neoplasia type 1 (MEN1)" *whole document, especially Introduction and Discussion sections*	1-5	
-/-			
The present search report has been drawn up for all claims			
Place of search MUNICH		Date of completion of the search 30 September 1996	Examiner Yeats, S
<p><b>CATEGORY OF CITED DOCUMENTS</b></p> <p>X: particularly relevant if taken alone Y: particularly relevant if combined with another document of the same category A: technological background O: non-written disclosure P: intermediate document</p> <p>T: theory or principle underlying the invention E: earlier patent document, but published on, or after the filing date D: document cited in the application L: document cited for other reasons</p> <p>A: member of the same patent family, corresponding document</p>			

EPO FORM 1503 (01.92) (P/C/D)

European Patent  
Office

## EUROPEAN SEARCH REPORT

Application Number  
EP 95 10 1980

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
P,X	HUM. MOL. GENET., vol. 3, 1994, pages 465-470, XP002014714 T. TODA ET AL.: "Isolation and characterization of a novel gene encoding nuclear protein at a locus (D11S636) tightly linked to multiple endocrine neoplasia type 1 (MEN1)" *whole document*	1-5	
			TECHNICAL FIELDS SEARCHED (Int.Cl.6)
The present search report has been drawn up for all claims			
Place of search MUNICH		Date of completion of the search 30 September 1996	Examiner Yeats, S
CATEGORY OF CITED DOCUMENTS X: particularly relevant if taken alone Y: particularly relevant if combined with another document of the same category A: technological background O: non-written disclosure P: intermediate document I: theory or principle underlying the invention E: earlier patent document, but published on, or after the filing date D: document cited in the application L: document cited for other reasons &: member of the same patent family, corresponding document			

EPO FORM 150 (01/91) (P4/C01)